Relation Extraction for Drug-Drug Interactions using Ensemble Learning
... for a case with exactly the same values for the features, i.e., it tries to find cases with exactly the same values for the mandatory features and matching as many optional features as possible. For the case retrieved in this step, a similarity between those and the original case is calculated by com ...
... for a case with exactly the same values for the features, i.e., it tries to find cases with exactly the same values for the mandatory features and matching as many optional features as possible. For the case retrieved in this step, a similarity between those and the original case is calculated by com ...
1 Multi-drug resistance gene (MDR1) and opioid analgesia
... agents and the risk of adverse effects associated with their use (KAMERLING, 1998). The objective of this review was to gather information on the influence of the MDR1 gene and opioid analgesia in horses. ...
... agents and the risk of adverse effects associated with their use (KAMERLING, 1998). The objective of this review was to gather information on the influence of the MDR1 gene and opioid analgesia in horses. ...
Center for Neuropharmacology and Neuroscience
... Enclosed are four copies of our revised manuscript (MS96MG-095) entitled, "Ibogaine And The Dopaminergic Response To Nicotine," authored by S.D. Glick, G.L. Mann, C.R. Deibel and myself which we would like to resubmit for publication in Psychopharmacology. 1- We do not think that it would be appropr ...
... Enclosed are four copies of our revised manuscript (MS96MG-095) entitled, "Ibogaine And The Dopaminergic Response To Nicotine," authored by S.D. Glick, G.L. Mann, C.R. Deibel and myself which we would like to resubmit for publication in Psychopharmacology. 1- We do not think that it would be appropr ...
2nd T. 5th L. Updated
... administering indomethacin to elderly patients or to those with underlying epilepsy, psychiatric disorders, or Parkinson's disease, because they are at greater risk for the development of serious CNS adverse effects Hematopoietic reactions include neutropenia, thrombocytopenia, and rarely aplastic ...
... administering indomethacin to elderly patients or to those with underlying epilepsy, psychiatric disorders, or Parkinson's disease, because they are at greater risk for the development of serious CNS adverse effects Hematopoietic reactions include neutropenia, thrombocytopenia, and rarely aplastic ...
... shall help us to detect the individuals who will experience the adverse reactions to medicines. This has become possible with the identification of SNPs (Single Nucleotide Polymorphisms). The variations in drug responses due to SNP play an important role. Polymorphisms in any one gene including thos ...
review
... agents and the risk of adverse effects associated with their use (KAMERLING, 1998). The objective of this review was to gather information on the influence of the MDR1 gene and opioid analgesia in horses. ...
... agents and the risk of adverse effects associated with their use (KAMERLING, 1998). The objective of this review was to gather information on the influence of the MDR1 gene and opioid analgesia in horses. ...
IOSR Journal of Applied Chemistry (IOSR-JAC)
... generation, 8-methoxyquinolone derivative of fluoroquinolone antibacterial agent, synthetic, active against a broad spectrum of pathogens, encompassing Gram-negative and Gram-positive bacteria. However, most of fluoroquinolones show miner side effect one of these is skin reaction including photosens ...
... generation, 8-methoxyquinolone derivative of fluoroquinolone antibacterial agent, synthetic, active against a broad spectrum of pathogens, encompassing Gram-negative and Gram-positive bacteria. However, most of fluoroquinolones show miner side effect one of these is skin reaction including photosens ...
Drug discovery and development: India
... the Drugs Controller of India granted CDRI permission to conduct Phase I clinical trials in healthy human volunteers. These trials did not reveal any undesirable effects. However, owing to the time that would have been required to conduct further clinical studies on purified bacosides, the decision ...
... the Drugs Controller of India granted CDRI permission to conduct Phase I clinical trials in healthy human volunteers. These trials did not reveal any undesirable effects. However, owing to the time that would have been required to conduct further clinical studies on purified bacosides, the decision ...
Acute Coronary Syndrome Therapeutic Intervention
... Plasminogen is an zymogen that is needed to breakdown fibrin clot in physiological mechanism 2. In order to activate the plasminogen into its active form; Plasmin, human kidneys secrete an enzyme called Urokinase. Urokinase will cleave the Plasminogen to Plasmin through proteolytic mechanism 3. Neve ...
... Plasminogen is an zymogen that is needed to breakdown fibrin clot in physiological mechanism 2. In order to activate the plasminogen into its active form; Plasmin, human kidneys secrete an enzyme called Urokinase. Urokinase will cleave the Plasminogen to Plasmin through proteolytic mechanism 3. Neve ...
Chapter 6: Mesoporous Silica: An Alternative Diffusion Controlled
... Some novel ceramic-based particulate systems for delivery and application of drug, such as antibiotics, growth factors and anticancer drug are claimed to have enhanced bioavailability, predictable therapeutic response and prolonged drug release time. Of particular interest are the biodegradable syst ...
... Some novel ceramic-based particulate systems for delivery and application of drug, such as antibiotics, growth factors and anticancer drug are claimed to have enhanced bioavailability, predictable therapeutic response and prolonged drug release time. Of particular interest are the biodegradable syst ...
Alcohol
... than vapors. However, vapors can actually get into the brain the most quickly. Perhaps worst of all, smoking is much more socially acceptable behavior than using needles or snorting due to our long history of accepting tobacco smoking. For this reason, when a drug is presented in smokeable form, a m ...
... than vapors. However, vapors can actually get into the brain the most quickly. Perhaps worst of all, smoking is much more socially acceptable behavior than using needles or snorting due to our long history of accepting tobacco smoking. For this reason, when a drug is presented in smokeable form, a m ...
Document
... This provision requires the front-end utilization of Generic medications covered under Tiers 1 & 2 at the beginning of a drug treatment program for new prescriptions. This requirement supports a continued focus on achieving higher generic drug utilization levels and reducing costs of the ...
... This provision requires the front-end utilization of Generic medications covered under Tiers 1 & 2 at the beginning of a drug treatment program for new prescriptions. This requirement supports a continued focus on achieving higher generic drug utilization levels and reducing costs of the ...
Hyoscine Butylbromide
... Disposition in the Body Poorly absorbed after oral administration. About 90% of an oral dose is eliminated in the faeces and <10% is excreted in the urine. After IV administration, about 40% of a dose is excreted in the urine. Halflife Plasma halflife, about 8 h. Protein Binding About 10%. Dose 2 ...
... Disposition in the Body Poorly absorbed after oral administration. About 90% of an oral dose is eliminated in the faeces and <10% is excreted in the urine. After IV administration, about 40% of a dose is excreted in the urine. Halflife Plasma halflife, about 8 h. Protein Binding About 10%. Dose 2 ...
Drug Discovery Strategies Today
... Pharmaceutical Industry – Success Rates of the R & D Process ...
... Pharmaceutical Industry – Success Rates of the R & D Process ...
The Use of Single Pill Combination Treatments in Patients
... including more than one dose of at least one (and often both) components. Hence the terms single-pill combination or flexible-dose combinations are preferred to the traditional meaning of FDCs. The use of FDC’s for the management of hypertension is limited in the UK, and much less commonly used than ...
... including more than one dose of at least one (and often both) components. Hence the terms single-pill combination or flexible-dose combinations are preferred to the traditional meaning of FDCs. The use of FDC’s for the management of hypertension is limited in the UK, and much less commonly used than ...
Why People Abuse Prescription Drugs “The Psychopharmacology of Addiction”
... PARTICULAR DRUGS AND MEDICATIONS THAT POSSESS A POTENTIAL FOR PSYCHOLOGICAL AND/OR PHYSICAL ABUSE AND DEPENDENCE INTO FIVE (5) ...
... PARTICULAR DRUGS AND MEDICATIONS THAT POSSESS A POTENTIAL FOR PSYCHOLOGICAL AND/OR PHYSICAL ABUSE AND DEPENDENCE INTO FIVE (5) ...
PRACTICE ON INTRAVENOUS DRUG PREPARATION AND
... theory was used to analyze the cause of IV errors. During 483 drug preparation and 447 drug administration, 265 IV drug errors were identified. The most common type of error committed was deliberate violation of guidelines when injecting bolus doses where the drug was administered faster than the r ...
... theory was used to analyze the cause of IV errors. During 483 drug preparation and 447 drug administration, 265 IV drug errors were identified. The most common type of error committed was deliberate violation of guidelines when injecting bolus doses where the drug was administered faster than the r ...
substance abuse drugs - University of the Sciences in Philadelphia
... • There is NO documented case worldwide of a fatal overdose from taking marijuana. ...
... • There is NO documented case worldwide of a fatal overdose from taking marijuana. ...
DEVELOPMENT AND VALIDATION OF LC-MS/MS METHOD FOR THE SIMULTANEOUS
... Step 1: Conditioned the HLB cartridge (30 mg/1cc) with 1.0 mL methanol, 1.0 mL of Milli-Q water, Step 2: Loaded sample, Step 3: Washed the cartridges with 1.0 mL of Milli-Q, followed by 1.0 mL of 5 % methanol, Step 4: Eluted the sample with 1.0 mL methanol, Step 5: Evaporated the eluate to dryness a ...
... Step 1: Conditioned the HLB cartridge (30 mg/1cc) with 1.0 mL methanol, 1.0 mL of Milli-Q water, Step 2: Loaded sample, Step 3: Washed the cartridges with 1.0 mL of Milli-Q, followed by 1.0 mL of 5 % methanol, Step 4: Eluted the sample with 1.0 mL methanol, Step 5: Evaporated the eluate to dryness a ...
Antifungal Agents
... inhibition of fungal cytochrome P450 enzymes. Greater affinity for funfal than for human cytochrome P450 enzymes. Imidazoles exhibit a lesser degree of specificity than the triazoles, accounting for their higher incidence of drug interactions and side effects. ...
... inhibition of fungal cytochrome P450 enzymes. Greater affinity for funfal than for human cytochrome P450 enzymes. Imidazoles exhibit a lesser degree of specificity than the triazoles, accounting for their higher incidence of drug interactions and side effects. ...
anxiolytics2011-09
... Pharmacokinetics: when given intravenously, it has a short half life (0.7-1.3 hr) due to rapid hepatic clearance. Clinical Uses: used for treating benzodiazepine overdose, in the reversal of deep sedative action of benzodiazepine when used during anesthesia, and to treat drowsiness and coma associat ...
... Pharmacokinetics: when given intravenously, it has a short half life (0.7-1.3 hr) due to rapid hepatic clearance. Clinical Uses: used for treating benzodiazepine overdose, in the reversal of deep sedative action of benzodiazepine when used during anesthesia, and to treat drowsiness and coma associat ...
Lorabid Prescribing Information
... to 50 mL/min/1.73 m2), following a single 400-mg dose, the plasma half-life was prolonged to approximately 5.6 hours. In subjects with severe renal impairment (creatinine clearance <10 mL/min/1.73 m2), the half-life was increased to approximately 32 hours. During hemodialysis the half-life was appro ...
... to 50 mL/min/1.73 m2), following a single 400-mg dose, the plasma half-life was prolonged to approximately 5.6 hours. In subjects with severe renal impairment (creatinine clearance <10 mL/min/1.73 m2), the half-life was increased to approximately 32 hours. During hemodialysis the half-life was appro ...
8BD 039 2 '03 JAN 24 AtI 114
... The label in Attachment 1 is representative of the look of the entire product IVSP family. As you can see, one of the issues BD faces with putting Drug Facts labeling on this kit label is the small size of the label. The attached label is close to actual size (approximately 5.25” x 3”). This same is ...
... The label in Attachment 1 is representative of the look of the entire product IVSP family. As you can see, one of the issues BD faces with putting Drug Facts labeling on this kit label is the small size of the label. The attached label is close to actual size (approximately 5.25” x 3”). This same is ...
Drug Safety Surveillance: Modern Trends and Industrial Action
... The primary aim of patient care is to provide the best medication that can produce the best treatment with minimal or no harm. This is only possible when the entire health care workers play their card well through correct prescription, dispensing, drug administration and adequate patient monitoring. ...
... The primary aim of patient care is to provide the best medication that can produce the best treatment with minimal or no harm. This is only possible when the entire health care workers play their card well through correct prescription, dispensing, drug administration and adequate patient monitoring. ...
Pharmacokinetics
Pharmacokinetics, sometimes abbreviated as PK (from Ancient Greek pharmakon ""drug"" and kinetikos ""moving, putting in motion""; see chemical kinetics), is a branch of pharmacology dedicated to determining the fate of substances administered externally to a living organism. The substances of interest include pharmaceutical agents, hormones, nutrients, and toxins. It attempts to discover the fate of a drug from the moment that it is administered up to the point at which it is completely eliminated from the body.Pharmacokinetics describes how the body affects a specific drug after administration through the mechanisms of absorption and distribution, as well as the chemical changes of the substance in the body (e.g. by metabolic enzymes such as cytochrome P450 or glucuronosyltransferase enzymes), and the effects and routes of excretion of the metabolites of the drug. Pharmacokinetic properties of drugs may be affected by elements such as the site of administration and the dose of administered drug. These may affect the absorption rate. Pharmacokinetics is often studied in conjunction with pharmacodynamics, the study of a drug's pharmacological effect on the body.A number of different models have been developed in order to simplify conceptualization of the many processes that take place in the interaction between an organism and a drug. One of these models, the multi-compartment model, gives the best approximation to reality; however, the complexity involved in using this type of model means that monocompartmental models and above all two compartmental models are the most-frequently used. The various compartments that the model is divided into are commonly referred to as the ADME scheme (also referred to as LADME if liberation is included as a separate step from absorption): Liberation - the process of release of a drug from the pharmaceutical formulation. See also IVIVC. Absorption - the process of a substance entering the blood circulation. Distribution - the dispersion or dissemination of substances throughout the fluids and tissues of the body. Metabolization (or biotransformation, or inactivation) – the recognition by the organism that a foreign substance is present and the irreversible transformation of parent compounds into daughter metabolites. Excretion - the removal of the substances from the body. In rare cases, some drugs irreversibly accumulate in body tissue.The two phases of metabolism and excretion can also be grouped together under the title elimination.The study of these distinct phases involves the use and manipulation of basic concepts in order to understand the process dynamics. For this reason in order to fully comprehend the kinetics of a drug it is necessary to have detailed knowledge of a number of factors such as: the properties of the substances that act as excipients, the characteristics of the appropriate biological membranes and the way that substances can cross them, or the characteristics of the enzyme reactions that inactivate the drug.All these concepts can be represented through mathematical formulas that have a corresponding graphical representation. The use of these models allows an understanding of the characteristics of a molecule, as well as how a particular drug will behave given information regarding some of its basic characteristics. Such as its acid dissociation constant (pKa), bioavailability and solubility, absorption capacity and distribution in the organism.The model outputs for a drug can be used in industry (for example, in calculating bioequivalence when designing generic drugs) or in the clinical application of pharmacokinetic concepts. Clinical pharmacokinetics provides many performance guidelines for effective and efficient use of drugs for human-health professionals and in veterinary medicine.